

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country.

<b>Study No.:</b> 113847 (Flu Q-Pan-H1N1-029)
<b>Title:</b> Safety and immunogenicity study of GSK Biologicals' pandemic influenza (H1N1) candidate vaccine (GSK2340274A) in Japanese children aged 6 months to 17 years. GSK2340274A (Flu): GlaxoSmithKline (GSK) Biologicals' A/California/7/2009 (H1N1)v-like vaccine adjuvanted with AS03A.
<b>Rationale:</b> The aim of this study is to assess the immunogenicity and safety of Flu vaccine in Japanese children using different formulations according to age (6 months to 9 years or 10 to 17 years). This summary presents results up to Day 42 and will be updated when additional data become available.
<b>Phase:</b> II
<b>Study Period:</b> From 27 October 2009 to 15 March 2010 (data lock point Day 42)
<b>Study Design:</b> Open study with two parallel groups.
<b>Centres:</b> 1 centre in Japan.
<b>Indication:</b> Immunization against A/California/7/2009 (H1N1)v-like influenza in children 6 months to 17 years of age.
<b>Treatment:</b> The study groups were as follow: <ul style="list-style-type: none"> <li>Flu [6 months-9 years] Group: Subjects aged from 6 months to 9 years received two doses of Flu vaccine (formulation 1) according to a 0, 21-day schedule. Within this group, enrolment of subjects was stratified by age into two subgroups, from 6 to 35 months and from 3 to 9 years.</li> <li>Flu [10-17 years] Group: Subjects aged from 10 to 17 years received two doses of Flu vaccine (formulation 2) according to a 0, 21-day schedule.</li> </ul> Flu vaccine, regardless of the formulation, was administered intramuscularly in the anterolateral part of the thigh (if the subject was less than 12 months) or in the deltoid region of the arm.
<b>Objectives:</b> <ul style="list-style-type: none"> <li>To assess whether vaccination with two doses of Flu vaccine (formulation 1) results in an immune response to the vaccine-homologous virus that meets or exceeds the U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER) and the European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP) guidance targets for pandemic vaccine seroconversion rate (SCR), rate of induction of vaccine-homologous reciprocal HI titres <math>\geq 40</math> (potential seroprotection rate or SPR), and geometric mean fold rise (GMFR) at 21 days after the second dose of Flu vaccine in children aged 6 months to 9 years (Flu [6 months-9 years] Group).</li> <li>To assess whether vaccination with two doses of Flu vaccine (formulation 2) results in an immune response to the vaccine-homologous virus that meets or exceeds the CBER and CHMP guidance targets for pandemic vaccine SCR, SPR, and GMFR at 21 days after the second dose of Flu vaccine in children aged 10 to 17 years (Flu [10-17 years] Group).</li> </ul> <p><i>The CBER Criteria was fulfilled for this study if after dose 2 in Flu [6 months-9 years] Group or Flu [10-17 years] Group :</i></p> <ul style="list-style-type: none"> <li><i>the lower 97.5% confidence interval for SCR was &gt; 40%, and</i></li> <li><i>the lower 97.5% confidence interval for SPR was &gt; 70%</i></li> </ul> <p><i>The CHMP Criteria was fulfilled for this study if after dose 2 in Flu [6 months-9 years] Group or Flu [10-17 years] Group :</i></p> <ul style="list-style-type: none"> <li><i>the point estimate for SCR was &gt; 40%, and</i></li> <li><i>the post-vaccination point estimate for SPR was &gt; 70%, and</i></li> <li><i>the point estimate for GMFR was &gt; 2.5.</i></li> </ul>
<b>Primary Outcome/Efficacy Variable:</b> <ul style="list-style-type: none"> <li>For the humoral immune response in terms of vaccine H1N1 HI antibodies against A/California/7/2009 (H1N1)v-like virus, the following parameters were calculated with 97.5% confidence intervals (CIs).</li> </ul> <p><i>Observed variable:</i></p> <ul style="list-style-type: none"> <li>- H1N1 HI antibodies on Day 42</li> </ul> <p><i>Derived variable:</i></p> <ul style="list-style-type: none"> <li>- Geometric Mean Titres (GMTs) of H1N1 HI antibodies;</li> <li>- SCR* on Day 42;</li> <li>- SPR** on Day 42;</li> <li>- GMFR*** on Day 42.</li> </ul> <p>*SCR is defined as the percentage of vaccinees that have either a pre-vaccination titre &lt; 1:10 and a postvaccination titre <math>\geq 1:40</math>, or a pre-vaccination titre <math>\geq 1:10</math> and at least a 4-fold increase in post-vaccination titre.</p>

\*\*SPR is defined as the percentage of vaccinees with a serum HI titre  $\geq 1:40$  that usually is accepted as indicating protection.

\*\*\*GMFR, also called seroconversion factor (SCF), is defined as the fold increase in serum HI GMTs post-vaccination compared to pre-vaccination.

#### **Secondary Outcome/Efficacy Variable(s):**

##### *Immunogenicity*

- For the humoral immune response in terms of H1N1 HI antibodies against A/California/7/2009 (H1N1)v-like virus, the following parameters were calculated with 95% CIs:

##### *Observed variable:*

- H1N1 HI antibodies on Day 0, Day 21, Day 42<sup>£</sup> and at Day 182<sup>#</sup>.

##### *Derived variable:*

- GMTs and seropositivity rates;
- SCRs;
- SPRs;
- GMFRs

The same analyses as above were performed in each age stratum.

- For the humoral immune response in terms of neutralising antibodies against A/California/7/2009 (H1N1)v-like virus, the following parameters were calculated with 95% CIs:<sup>§</sup>

##### *Observed variable:*

- Serum neutralising antibody titres on Day 0, Day 21, Day 42 and Day 182.

##### *Derived variable:*

- GMTs and seropositivity rates;
- VRRs\*;

\*VRR is defined as the percentage of vaccinees that have a four-fold increase between pre- and postvaccination titres.

##### *Safety:*

- Percentage, intensity and relationship to vaccination of solicited local and general signs and symptoms during a 7-day follow-up period, i.e., day of vaccination and six subsequent days after each vaccination on Day 0 and Day 21.
- Percentage, intensity and relationship to vaccination of unsolicited adverse events (AEs) during a 21-day follow-up period after the first vaccination and during a 63-day follow-up period after the second vaccination. #
- Occurrence of medically attended events (MAEs), potential Immune-Mediated Diseases (pIMDs), serious adverse events (SAEs) and relationship to vaccination during the entire study period. #
- The number and percentage of subjects with normal or abnormal values of biochemical and haematological parameters on Day 0, Day 7 and Day 42.

£ Analyses based on 95% CI for 10-17 year age category at Day 42 not performed.

# At the time of writing this summary, data were available up to Day 42 only. This summary will be updated when additional results become available.

§ Not available at the time of writing this summary.

#### **Statistical Methods:**

Analyses were performed on the Total Vaccinated cohort for safety analyses, the According-To-Protocol (ATP) cohort for immunogenicity at Day 21 and the ATP cohort for immunogenicity at Day 42.

- The Total Vaccinated cohort included all vaccinated subjects.
- The ATP cohort for immunogenicity at Day 21 included all evaluable subjects (i.e., those meeting all eligibility criteria, complying with the procedures defined in the protocol, with no elimination criteria during the study) for whom no immunoglobulins and/or any blood products were administered during the relevant study period (Days 0 - 21), for whom there was no chronic administration of immunosuppressants (e.g., prednisone  $\geq 0.5$  mg/kg/day, for more than 14 consecutive days) or administration of other immune-modifying drugs during the relevant study period, who received the vaccine dose on Day 0 per protocol treatment assignment and for whom assay results for antibodies against A/California-like HA antigen for the blood sample taken 21 days after the first vaccination were available.
- The ATP cohort for immunogenicity at Day 42 included all evaluable subjects (i.e., those meeting all eligibility criteria, complying with the procedures defined in the protocol, with no elimination criteria during the study) for whom no immunoglobulins and/or any blood products were administered during the relevant study period (Days 0 - 42), for whom there was no chronic administration of immunosuppressants (e.g., prednisone  $\geq 0.5$  mg/kg/day, for more than 14 consecutive days) or administration of other immune-modifying drugs during the relevant study period, who received the vaccine doses on both Day 0 and Day 21 per protocol treatment assignment and for whom assay results for antibodies against A/California-like HA antigen for the blood samples taken on Day 42 (21 days after the second vaccinations) were available.

**Analysis of immunogenicity:**

The analysis of immunogenicity was done as a descriptive analysis of the humoral immune response. For the humoral immune response in terms of H1N1 HI antibodies, the following parameters were calculated (with 97.5% CIs):

- Seropositivity rates and GMTs of H1N1 HI antibody titres at Day 0 and Day 42.
- SCR at Day 42.
- SPR at Day 0 and Day 42.
- GMFR at Day 42.

The same parameters were also calculated with 95% CI at Day 21 and Day 42 and in each age stratum.

**Analysis of safety:**

The incidence of solicited local and general symptoms occurring during 7 days after each vaccination was tabulated with exact 95% CI for each treatment group. The same calculations were performed for symptoms of any intensity, those with intensity of Grade 3, as well as for solicited general events with relationship to vaccination. All solicited local AEs were assessed as causally related per protocol.

The percentage of subjects with at least one report of an unsolicited AE classified by Medical Dictionary for Regulatory Activities (MedDRA) Preferred Term up to 42 days after the first dose of vaccine was tabulated for each treatment group. The same tabulation was performed for grade 3 unsolicited AEs and for unsolicited AEs that were assessed by the investigator as related to vaccination.

SAEs, MAEs and pIMDs were collected and summarized up to Day 42.

Safety laboratory data were also summarized by vaccine treatment group and tabulated over time.

**Study Population:** Healthy male or female Japanese children aged between 6 months to 17 years of age at the time of first vaccination, inclusive. Female subjects of childbearing potential had to practice adequate contraception for 30 days prior to vaccination, to have a negative pregnancy test and to continue such precautions for 2 months after completion of the vaccination series. Written informed consent was obtained from the subject's parent(s) or Legally Acceptable Representative(s) of the subject prior to study entry. Whenever possible, an assent was also obtained from the subject.

Number of subjects	Flu [6 months-9 years] Group	Flu [10-17 years] Group
Planned, N	30	30
Randomised, N (Total Vaccinated cohort)	30	30
Completed to Day 42, n (%)	28 (93.3)	30 (100)
Total Number Subjects Withdrawn, n (%)	2 (6.7)	0 (0.0)
Withdrawn due to Adverse Events, n (%)	0 (0.0)	0 (0.0)
Withdrawn due to Lack of Efficacy, n (%)	Not applicable	Not applicable
Withdrawn for other reasons, n (%)	2 (6.7)	0 (0.0)
Demographics	Flu [6 months-9 years] Group	Flu [10-17 years] Group
N (Total Vaccinated Cohort)	30	30
Females:Males	16:14	18:12
Mean Age, months (SD)	49.0 (27.66)	163.0 (32.41)
Asian - japanese heritage, n (%)	30 (100)	30 (100)

**Primary Efficacy Results:** Seropositivity rates and GMTs for HI antibodies against Flu A/CAL/7/09 (ATP cohort for immunogenicity at Day 42)

Antibody against	Group	Timing	N	≥ 1:10				GMT		
				n	%	97.5% CI		value	97.5% CI	
						LL	UL		LL	UL
Flu A/CAL/7/09	Flu [6 months-9 years]	PRE	28	5	17.9	5.1	39.6	6.4	4.8	8.5
		PII(D42)	28	28	100	85.5	100	939.3	722.9	1220.6
	Flu [10-17 years]	PRE	30	18	60.0	38.2	79.3	15.3	8.8	26.5
		PII(D42)	30	30	100	86.4	100	874.3	717.4	1065.4

GMT = geometric mean antibody titre calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with titre within the specified range

97.5% CI = 97.5% confidence interval; LL = Lower Limit, UL = Upper Limit

PRE= pre-vaccination (Day 0)

PII(D42)= post dose 2 (Day 42)										
<b>Primary Efficacy Results:</b> SCR for HI antibodies against Flu A/CAL/7/09 at Day 42 (ATP cohort for immunogenicity at Day 42)										
				<b>SCR</b>						
				<b>97.5% CI</b>						
<b>Antibody against</b>	<b>Group</b>	<b>Timing</b>	<b>N</b>	<b>n</b>	<b>%</b>	<b>LL</b>	<b>UL</b>			
Flu A/CAL/7/09	Flu [6 months-9 years]	PII(D42)	28	28	100	85.5	100			
	Flu [10-17 years]	PII(D42)	30	30	100	86.4	100			
Seroconversion defined as: For initially seronegative subjects, antibody titre $\geq$ 1:40 after vaccination For initially seropositive subjects, antibody titre after vaccination $\geq$ 4 fold the pre-vaccination antibody titre N = Number of subjects with pre- and post-vaccination results available n/% = Number/percentage of seroconverted subjects 97.5% CI = 97.5% confidence interval, LL = Lower Limit, UL = Upper Limit PII(D42)= post dose 2 (Day 42)										
<b>Primary Efficacy Results:</b> SPR for HI antibodies against Flu A/CAL/7/09 at Day 0, and Day 42 (ATP cohort for immunogenicity at Day 42)										
				<b>SPR</b>						
				<b>97.5% CI</b>						
<b>Antibody against</b>	<b>Group</b>	<b>Timing</b>	<b>N</b>	<b>n</b>	<b>%</b>	<b>LL</b>	<b>UL</b>			
Flu A/CAL/7/09	Flu [6 months-9 years]	PRE	28	1	3.6	0.0	20.7			
		PII(D42)	28	28	100	85.5	100			
	Flu [10-17 years]	PRE	30	8	26.7	10.8	48.5			
		PII(D42)	30	30	100	86.4	100			
N = Number of subjects with available results n/% = Number/percentage of seroprotected subjects (HI titre $\geq$ 1:40) 97.5% CI = 97.5% confidence interval, LL = Lower Limit, UL = Upper Limit PRE= pre-vaccination (Day 0) PII(D42)= post dose 2 (Day 42)										
<b>Primary Efficacy Results:</b> SCF for HI antibodies against Flu A/CAL/7/09 at Day 42 (ATP cohort for immunogenicity at Day 42)										
				<b>SCF</b>						
				<b>97.5% CI</b>						
<b>Antibody against</b>	<b>Group</b>	<b>Timing</b>	<b>N</b>	<b>Value</b>	<b>LL</b>	<b>UL</b>				
Flu A/CAL/7/09 (1/DIL)	Flu [6 months-9 years]	PII(D42)	28	146.8	99.6	216.4				
	Flu [10-17 years]	PII(D42)	30	57.1	33.5	97.3				
N = Number of subjects with pre- and post-vaccination results available SCF = Fold increase in serum HI GMTs post-vaccination 97.5% CI = 97.5% confidence interval, LL = Lower Limit, UL = Upper Limit PII(D42)= post dose 2 (Day 42)										
<b>Secondary Outcome Variable(s):</b> Seropositivity rates and GMTs for HI antibodies against Flu A/CAL/7/09 (ATP cohort for immunogenicity at Day 21)										
				<b><math>\geq</math> 1:10</b>				<b>GMT</b>		
				<b>95% CI</b>				<b>95% CI</b>		
<b>Antibody against</b>	<b>Group</b>	<b>Timing</b>	<b>N</b>	<b>n</b>	<b>%</b>	<b>LL</b>	<b>UL</b>	<b>value</b>	<b>LL</b>	<b>UL</b>
Flu A/CAL/7/09.	Flu [6 months-9 years]	PRE	29	5	17.2	5.8	35.8	6.3	5.0	8.1
		PI(D21)	29	29	100	88.1	100	172.0	130.1	227.6
	Flu [10-17 years]	PRE	30	18	60.0	40.6	77.3	15.3	9.5	24.6
		PI(D21)	30	30	100	88.4	100	339.0	238.8	481.2
GMT = geometric mean antibody titre calculated on all subjects N = number of subjects with available results n/% = number/percentage of subjects with titre within the specified range 95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit PRE= pre-vaccination (Day 0) PI(D21)= post dose 1 (Day 21)										

<b>Secondary Outcome Variable(s):</b> Seropositivity rates and GMTs for HI antibodies against Flu A/CAL/7/09 in Flu [6 months-9 years] Group, by age strata (ATP cohort for immunogenicity at Day 21)											
							≥ 1:10		GMT		
							95% CI		95% CI		
Antibody against	Group	Sub-group	Timing	N	n	%	LL	UL	value	LL	UL
Flu A/CAL/7/09	Flu [6 months-9 years]	6m-35m	PRE	10	0	0.0	0.0	30.8	5.0	5.0	5.0
			PI(D21)	10	10	100	69.2	100	117.3	72.2	190.8
		3y-9y	PRE	19	5	26.3	9.1	51.2	7.2	5.0	10.3
			PI(D21)	19	19	100	82.4	100	210.4	150.4	294.5
GMT = geometric mean antibody titre calculated on all subjects N = number of subjects with available results n/% = number/percentage of subjects with titre within the specified range 95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit PRE= pre-vaccination (Day 0) PI(D21)= post dose 1 (Day 21)											
<b>Secondary Outcome Variable(s):</b> Seropositivity rates and GMTs for HI antibodies against Flu A/CAL/7/09 in Flu [6 months-9 years] Group, by age strata (ATP cohort for immunogenicity at Day 42)											
							≥ 1:10		GMT		
							95% CI		95% CI		
Antibody against	Group	Sub-group	Timing	N	n	%	LL	UL	value	LL	UL
Flu A/CAL/7/09	Flu [6 months-9 years]	6m-35m	PRE	9	0	0.0	0.0	33.6	5.0	5.0	5.0
			PII(D42)	9	9	100	66.4	100	1279.9	806.9	2030.4
		3y-9y	PRE	19	5	26.3	9.1	51.2	7.2	5.0	10.3
			PII(D42)	19	19	100	82.4	100	811.3	628.4	1047.4
GMT = geometric mean antibody titre calculated on all subjects N = number of subjects with available results n/% = number/percentage of subjects with titre within the specified range 95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit PRE= pre-vaccination (Day 0) PII(D42)= post dose 2 (Day 42)											
<b>Secondary Outcome Variable(s):</b> SCR for HI antibodies against Flu A/CAL/7/09 at Day 21 (ATP cohort for immunogenicity at Day 21)											
							SCR				
							95% CI				
Antibody against	Group	Timing	N	n	%	LL	UL				
Flu A/CAL/7/09	Flu [6 months-9 years]	PI(D21)	29	29	100	88.1	100				
	Flu [10-17 years]	PI(D21)	30	27	90.0	73.5	97.9				
Seroconversion defined as: For initially seronegative subjects, antibody titre ≥ 1:40 after vaccination For initially seropositive subjects, antibody titre after vaccination ≥ 4 fold the pre-vaccination antibody titre N = Number of subjects with pre- and post-vaccination results available n/% = Number/percentage of seroconverted subjects 95% CI = 95% confidence interval, LL = Lower Limit, UL = Upper Limit PI(D21)= post dose 1 (Day 21)											
<b>Secondary Outcome Variable(s):</b> SCR for HI antibodies against Flu A/CAL/7/09 at Day 21 in Flu [6 months-9 years] Group, by age strata (ATP cohort for immunogenicity at Day 21)											
							SCR				
							95% CI				
Antibody against	Group	Sub-group	Timing	N	n	%	LL	UL			
Flu A/CAL/7/09	Flu [6 months-9 years]	6m-35m	PI(D21)	10	10	100	69.2	100			
		3y-9y	PI(D21)	19	19	100	82.4	100			
Seroconversion defined as: For initially seronegative subjects, antibody titre ≥ 1:40 after vaccination For initially seropositive subjects, antibody titre after vaccination ≥ 4 fold the pre-vaccination antibody titre											

<p>N = Number of subjects with pre- and post-vaccination results available  n/% = Number/percentage of seroconverted subjects  95% CI = 95% confidence interval, LL = Lower Limit, UL = Upper Limit  PI(D21)= post dose 1 (Day 21)</p>								
<p><b>Secondary Outcome Variable(s):</b> SCR for HI antibodies against Flu A/CAL/7/09 at Day 42 in Flu [6 months-9 years] Group, by age strata (ATP cohort for immunogenicity at Day 42)</p>								
						<b>SCR</b>		
						<b>95% CI</b>		
Antibody against	Group	Sub-group	Timing	N	n	%	LL	UL
Flu A/CAL/7/09	Flu [6 months-9 years]	6m-35m	PII(D42)	9	9	100	66.4	100
		3y-9y	PII(D42)	19	19	100	82.4	100
<p>Seroconversion defined as:  For initially seronegative subjects, antibody titre <math>\geq</math> 1:40 after vaccination  For initially seropositive subjects, antibody titre after vaccination <math>\geq</math> 4 fold the pre-vaccination antibody titre  N = Number of subjects with pre- and post-vaccination results available  n/% = Number/percentage of seroconverted subjects  95% CI = 95% confidence interval, LL = Lower Limit, UL = Upper Limit  PII(D42)= post dose 2 (Day 42)</p>								
<p><b>Secondary Outcome Variable(s):</b> SPR for HI antibodies against Flu A/CAL/7/09 at Day 0 and Day 21 (ATP cohort for immunogenicity at Day 21)</p>								
						<b>SPR</b>		
						<b>95% CI</b>		
Antibody against	Group	Timing	N	n	%	LL	UL	
Flu A/CAL/7/09	Flu [6 months-9 years]	PRE	29	1	3.4	0.1	17.8	
		PI(D21)	29	29	100	88.1	100	
	Flu [10-17 years]	PRE	30	8	26.7	12.3	45.9	
		PI(D21)	30	29	96.7	82.8	99.9	
<p>N = Number of subjects with available results  n/% = Number/percentage of seroprotected subjects (HI titre <math>\geq</math> 1:40)  95% CI = 95% confidence interval, LL = Lower Limit, UL = Upper Limit  PRE= pre-vaccination (Day 0)  PI(D21)= post dose 1 (Day 21)</p>								
<p><b>Secondary Outcome Variable(s):</b> SPR for HI antibodies against Flu A/CAL/7/09 at Day 0 and Day 21 in Flu [6 months-9 years] Group, by age strata (ATP cohort for immunogenicity at Day 21)</p>								
						<b>SPR</b>		
						<b>95% CI</b>		
Antibody against	Group	Sub-group	Timing	N	n	%	LL	UL
Flu A/CAL/7/09	Flu [6 months-9 years]	6m-35m	PRE	10	0	0.0	0.0	30.8
			PI(D21)	10	10	100	69.2	100
		3y-9y	PRE	19	1	5.3	0.1	26.0
			PI(D21)	19	19	100	82.4	100
<p>N = Number of subjects with available results  n/% = Number/percentage of seroprotected subjects (HI titre <math>\geq</math> 1:40)  95% CI = 95% confidence interval, LL = Lower Limit, UL = Upper Limit  PRE= pre-vaccination (Day 0)  PI(D21)= post dose 1 (Day 21)</p>								
<p><b>Secondary Outcome Variable(s):</b> SPR for HI antibodies against Flu A/CAL/7/09 at Day 0, and Day 42 in Flu [6 months-9 years] Group, by age strata (ATP cohort for immunogenicity at Day 42)</p>								
						<b>SPR</b>		
						<b>95% CI</b>		
Antibody against	Group	Sub-group	Timing	N	n	%	LL	UL
Flu A/CAL/7/09	Flu [6 months-9 years]	6m-35m	PRE	9	0	0.0	0.0	33.6
			PII(D42)	9	9	100	66.4	100
		3y-9y	PRE	19	1	5.3	0.1	26.0
			PII(D42)	19	19	100	82.4	100
<p>N = Number of subjects with available results</p>								

<p>n/% = Number/percentage of seroprotected subjects (HI titre <math>\geq</math> 1:40)  95% CI = 95% confidence interval, LL = Lower Limit, UL = Upper Limit  PRE= pre-vaccination (Day 0)  PII(D42)= post dose 2 (Day42)</p>																
<p><b>Secondary Outcome Variable(s):</b> SCF for HI antibodies against Flu A/CAL/7/09 at Day 21 (ATP cohort for immunogenicity at Day 21)</p>																
													<b>SCF</b>			
													<b>95% CI</b>			
<b>Antibody against</b>		<b>Group</b>			<b>Timing</b>			<b>N</b>		<b>Value</b>		<b>LL</b>		<b>UL</b>		
Flu A/CAL/7/09 (1/DIL)		Flu [6 months-9 years]			PI(D21)			29		27.1		20.4		36.1		
		Flu [10-17 years]			PI(D21)			30		22.1		13.6		35.9		
<p>N = Number of subjects with pre- and post-vaccination results available  SCF = Fold increase in serum HI GMTs post-vaccination  95% CI = 95% confidence interval, LL = Lower Limit, UL = Upper Limit  PI(D21)= post dose 1 (Day 21)</p>																
<p><b>Secondary Outcome Variable(s):</b> SCF for HI antibodies against Flu A/CAL/7/09 at Day 21 in Flu [6 months-9 years] Group, by age strata (ATP cohort for immunogenicity at Day 21)</p>																
													<b>SCF</b>			
													<b>95% CI</b>			
<b>Antibody against</b>		<b>Group</b>			<b>Sub-group</b>		<b>Timing</b>		<b>N</b>		<b>Value</b>		<b>LL</b>		<b>UL</b>	
Flu A/CAL/7/09 (1/DIL)		Flu [6 months-9 years]			6m-35m		PI(D21)		10		23.5		14.4		38.2	
					3y-9y		PI(D21)		19		29.3		19.9		42.9	
<p>N = Number of subjects with pre- and post-vaccination results available  SCF = Fold increase in serum HI GMTs post-vaccination  95% CI = 95% confidence interval, LL = Lower Limit, UL = Upper Limit  PI(D21)= post dose 1 (Day 21)</p>																
<p><b>Secondary Outcome Variable(s):</b> SCF for HI antibodies against Flu A/CAL/7/09 at Day 42 in Flu [6 months-9 years] Group, by age strata (ATP cohort for immunogenicity at Day 42)</p>																
													<b>SCF</b>			
													<b>95% CI</b>			
<b>Antibody against</b>		<b>Group</b>			<b>Sub-group</b>		<b>Timing</b>		<b>N</b>		<b>Value</b>		<b>LL</b>		<b>UL</b>	
Flu A/CAL/7/09 (1/DIL)		Flu [6 months-9 years]			6m-35m		PII(D42)		9		256.0		161.4		406.1	
					3y-9y		PII(D42)		19		112.8		74.6		170.5	
<p>N = Number of subjects with pre- and post-vaccination results available  SCF = Fold increase in serum HI GMTs post-vaccination  95% CI = 95% confidence interval, LL = Lower Limit, UL = Upper Limit  PII(D42)= post dose 2 (Day 42)</p>																
<p><b>Secondary Outcome Variable(s):</b> Incidence of solicited local symptoms reported during the 7-day (Days 0-6) post-vaccination period following each dose and overall (Total Vaccinated cohort)</p>																
<b>Flu [6 months-9 years] Group</b>																
<b>Flu [10-17 years] Group</b>																
<b>6m-5y</b>																
<b>6y-9y</b>																
<b>10-17y</b>																
<b>95 % CI</b>																
<b>95 % CI</b>																
<b>Symptom</b>	<b>Intensity</b>	<b>N</b>	<b>n</b>	<b>%</b>	<b>LL</b>	<b>UL</b>	<b>N</b>	<b>n</b>	<b>%</b>	<b>LL</b>	<b>UL</b>	<b>N</b>	<b>n</b>	<b>%</b>	<b>LL</b>	<b>UL</b>
<b>Dose 1</b>																
Pain	Any	24	19	79.2	57.8	92.9	6	5	83.3	35.9	99.6	30	30	100	88.4	100
	Grade 3	24	1	4.2	0.1	21.1	6	0	0.0	0.0	45.9	30	3	10.0	2.1	26.5
Redness	Any	24	0	0.0	0.0	14.2	6	1	16.7	0.4	64.1	30	7	23.3	9.9	42.3
	>100 mm	24	0	0.0	0.0	14.2	6	0	0.0	0.0	45.9	30	0	0.0	0.0	11.6
Swelling	Any	24	5	20.8	7.1	42.2	6	2	33.3	4.3	77.7	30	14	46.7	28.3	65.7
	>100 mm	24	0	0.0	0.0	14.2	6	0	0.0	0.0	45.9	30	1	3.3	0.1	17.2
<b>Dose 2</b>																
Pain	Any	23	16	69.6	47.1	86.8	6	5	83.3	35.9	99.6	30	30	100	88.4	100
	Grade 3	23	1	4.3	0.1	21.9	6	0	0.0	0.0	45.9	30	2	6.7	0.8	22.1
Redness	Any	23	2	8.7	1.1	28.0	6	0	0.0	0.0	45.9	30	5	16.7	5.6	34.7
	>100 mm	23	0	0.0	0.0	14.8	6	0	0.0	0.0	45.9	30	0	0.0	0.0	11.6
Swelling	Any	23	4	17.4	5.0	38.8	6	2	33.3	4.3	77.7	30	15	50.0	31.3	68.7

	>100 mm	23	0	0.0	0.0	14.8	6	0	0.0	0.0	45.9	30	1	3.3	0.1	17.2
<b>Across doses</b>																
Pain	Any	24	19	79.2	57.8	92.9	6	6	100	54.1	100	30	30	100	88.4	100
	Grade 3	24	2	8.3	1.0	27.0	6	0	0.0	0.0	45.9	30	5	16.7	5.6	34.7
Redness	Any	24	2	8.3	1.0	27.0	6	1	16.7	0.4	64.1	30	10	33.3	17.3	52.8
	>100 mm	24	0	0.0	0.0	14.2	6	0	0.0	0.0	45.9	30	0	0.0	0.0	11.6
Swelling	Any	24	8	33.3	15.6	55.3	6	2	33.3	4.3	77.7	30	16	53.3	34.3	71.7
	>100 mm	24	0	0.0	0.0	14.2	6	0	0.0	0.0	45.9	30	2	6.7	0.8	22.1

N= number of subjects with at least one documented dose

n/%= number/percentage of subjects reporting at least once the symptom

95%CI= Exact 95% confidence interval; LL = lower limit, UL = upper limit

Any= occurrence of any local symptoms regardless of their intensity grade

Grade 3 pain (child < 6 years) = cried when limb was moved/spontaneously painful

Grade 3 pain (child ≥ 6 years) = pain that prevented normal activity

**Secondary Outcome Variable(s):** Incidence of solicited general symptoms reported during the 7-day (Day 0-6) post-vaccination period following each dose and overall in subjects aged 6mth-5yrs (Total Vaccinated cohort)

		<b>Flu [6 months-9 years] Group</b>				
		<b>6m-5y</b>			<b>95 % CI</b>	
<b>Symptom</b>	<b>Intensity/ Relationship</b>	<b>N</b>	<b>n</b>	<b>%</b>	<b>LL</b>	<b>UL</b>
<b>Dose 1</b>						
Drowsiness	Any	24	5	20.8	7.1	42.2
	Grade 3	24	0	0.0	0.0	14.2
	Related	24	5	20.8	7.1	42.2
Irritability	Any	24	6	25.0	9.8	46.7
	Grade 3	24	1	4.2	0.1	21.1
	Related	24	6	25.0	9.8	46.7
Loss of appetite	Any	24	5	20.8	7.1	42.2
	Grade 3	24	0	0.0	0.0	14.2
	Related	24	4	16.7	4.7	37.4
Temperature (Axillary)	≥ 37.5°C	24	3	12.5	2.7	32.4
	≥ 39.0°C - ≤ 40.0°C	24	0	0.0	0.0	14.2
	Related	24	3	12.5	2.7	32.4
<b>Dose 2</b>						
Drowsiness	Any	23	7	30.4	13.2	52.9
	Grade 3	23	0	0.0	0.0	14.8
	Related	23	7	30.4	13.2	52.9
Irritability	Any	23	6	26.1	10.2	48.4
	Grade 3	23	0	0.0	0.0	14.8
	Related	23	5	21.7	7.5	43.7
Loss of appetite	Any	23	5	21.7	7.5	43.7
	Grade 3	23	1	4.3	0.1	21.9
	Related	23	5	21.7	7.5	43.7
Temperature (Axillary)	≥ 37.5°C	23	6	26.1	10.2	48.4
	≥ 39.0°C - ≤ 40.0°C	23	2	8.7	1.1	28.0
	Related	23	5	21.7	7.5	43.7
<b>Across doses</b>						
Drowsiness	Any	24	8	33.3	15.6	55.3
	Grade 3	24	0	0.0	0.0	14.2
	Related	24	8	33.3	15.6	55.3
Irritability	Any	24	8	33.3	15.6	55.3
	Grade 3	24	1	4.2	0.1	21.1
	Related	24	7	29.2	12.6	51.1
Loss of appetite	Any	24	7	29.2	12.6	51.1
	Grade 3	24	1	4.2	0.1	21.1

	Related	24	6	25.0	9.8	46.7					
Temperature (Axillary)	≥ 37.5°C	24	8	33.3	15.6	55.3					
	≥ 39.0°C - ≤ 40.0°C	24	2	8.3	1.0	27.0					
	Related	24	7	29.2	12.6	51.1					
<p>N= number of subjects with at least one documented dose  n/%= number/percentage of subjects reporting at least once the symptom  95%CI= Exact 95% confidence interval; LL = lower limit, UL = upper limit  Any= occurrence of any general symptoms regardless of their intensity grade or their relation to vaccination  Grade 3 irritability and drowsiness= symptom that prevented normal activity  Grade 3 loss of appetite= not eating at all  Related= symptom assessed by the investigator as causally related to the study vaccination</p>											
<b>Secondary Outcome Variable(s):</b> Incidence of solicited general symptoms reported during the 7-day (Day 0-6) post-vaccination period following each dose and overall in subjects aged 6yrs-9yrs and 10yrs-17yrs (Total Vaccinated cohort)											
		Flu [6 months-9 years] Group					Flu [10-17 years] Group				
		6y-9y					10-17y				
		95 % CI					95 % CI				
<b>Symptom</b>	<b>Intensity/Relationship</b>	<b>N</b>	<b>n</b>	<b>%</b>	<b>LL</b>	<b>UL</b>	<b>N</b>	<b>n</b>	<b>%</b>	<b>LL</b>	<b>UL</b>
<b>Dose 1</b>											
Fatigue	Any	6	1	16.7	0.4	64.1	30	11	36.7	19.9	56.1
	Grade 3	6	0	0.0	0.0	45.9	30	1	3.3	0.1	17.2
	Related	6	0	0.0	0.0	45.9	30	10	33.3	17.3	52.8
Gastrointestinal	Any	6	1	16.7	0.4	64.1	30	3	10.0	2.1	26.5
	Grade 3	6	0	0.0	0.0	45.9	30	0	0.0	0.0	11.6
	Related	6	0	0.0	0.0	45.9	30	3	10.0	2.1	26.5
Headache	Any	6	2	33.3	4.3	77.7	30	12	40.0	22.7	59.4
	Grade 3	6	0	0.0	0.0	45.9	30	0	0.0	0.0	11.6
	Related	6	0	0.0	0.0	45.9	30	11	36.7	19.9	56.1
Joint pain at other location	Any	6	0	0.0	0.0	45.9	30	5	16.7	5.6	34.7
	Grade 3	6	0	0.0	0.0	45.9	30	0	0.0	0.0	11.6
	Related	6	0	0.0	0.0	45.9	30	4	13.3	3.8	30.7
Muscle aches	Any	6	0	0.0	0.0	45.9	30	7	23.3	9.9	42.3
	Grade 3	6	0	0.0	0.0	45.9	30	0	0.0	0.0	11.6
	Related	6	0	0.0	0.0	45.9	30	7	23.3	9.9	42.3
Shivering	Any	6	1	16.7	0.4	64.1	30	7	23.3	9.9	42.3
	Grade 3	6	0	0.0	0.0	45.9	30	0	0.0	0.0	11.6
	Related	6	1	16.7	0.4	64.1	30	6	20.0	7.7	38.6
Sweating	Any	6	0	0.0	0.0	45.9	30	2	6.7	0.8	22.1
	Grade 3	6	0	0.0	0.0	45.9	30	1	3.3	0.1	17.2
	Related	6	0	0.0	0.0	45.9	30	1	3.3	0.1	17.2
Temperature (Axillary)	≥ 37.5°C	6	2	33.3	4.3	77.7	30	4	13.3	3.8	30.7
	≥ 39.0°C - ≤ 40.0°C	6	0	0.0	0.0	45.9	30	3	10.0	2.1	26.5
	Related	6	1	16.7	0.4	64.1	30	3	10.0	2.1	26.5
<b>Dose 2</b>											
Fatigue	Any	6	1	16.7	0.4	64.1	30	11	36.7	19.9	56.1
	Grade 3	6	0	0.0	0.0	45.9	30	1	3.3	0.1	17.2
	Related	6	1	16.7	0.4	64.1	30	11	36.7	19.9	56.1
Gastrointestinal	Any	6	1	16.7	0.4	64.1	30	3	10.0	2.1	26.5
	Grade 3	6	0	0.0	0.0	45.9	30	0	0.0	0.0	11.6
	Related	6	1	16.7	0.4	64.1	30	3	10.0	2.1	26.5
Headache	Any	6	1	16.7	0.4	64.1	30	17	56.7	37.4	74.5
	Grade 3	6	0	0.0	0.0	45.9	30	2	6.7	0.8	22.1
	Related	6	1	16.7	0.4	64.1	30	16	53.3	34.3	71.7
Joint pain at other	Any	6	0	0.0	0.0	45.9	30	7	23.3	9.9	42.3

location	Grade 3	6	0	0.0	0.0	45.9	30	0	0.0	0.0	11.6
	Related	6	0	0.0	0.0	45.9	30	6	20.0	7.7	38.6
Muscle aches	Any	6	0	0.0	0.0	45.9	30	9	30.0	14.7	49.4
	Grade 3	6	0	0.0	0.0	45.9	30	0	0.0	0.0	11.6
	Related	6	0	0.0	0.0	45.9	30	8	26.7	12.3	45.9
Shivering	Any	6	0	0.0	0.0	45.9	30	8	26.7	12.3	45.9
	Grade 3	6	0	0.0	0.0	45.9	30	0	0.0	0.0	11.6
	Related	6	0	0.0	0.0	45.9	30	8	26.7	12.3	45.9
Sweating	Any	6	0	0.0	0.0	45.9	30	3	10.0	2.1	26.5
	Grade 3	6	0	0.0	0.0	45.9	30	0	0.0	0.0	11.6
	Related	6	0	0.0	0.0	45.9	30	3	10.0	2.1	26.5
Temperature (Axillary)	≥ 37.5°C	6	0	0.0	0.0	45.9	30	7	23.3	9.9	42.3
	≥ 39.0°C - ≤ 40.0°C	6	0	0.0	0.0	45.9	30	0	0.0	0.0	11.6
	Related	6	0	0.0	0.0	45.9	30	7	23.3	9.9	42.3
<b>Across doses</b>											
Fatigue	Any	6	2	33.3	4.3	77.7	30	14	46.7	28.3	65.7
	Grade 3	6	0	0.0	0.0	45.9	30	2	6.7	0.8	22.1
	Related	6	1	16.7	0.4	64.1	30	14	46.7	28.3	65.7
Gastrointestinal	Any	6	2	33.3	4.3	77.7	30	4	13.3	3.8	30.7
	Grade 3	6	0	0.0	0.0	45.9	30	0	0.0	0.0	11.6
	Related	6	1	16.7	0.4	64.1	30	4	13.3	3.8	30.7
Headache	Any	6	3	50.0	11.8	88.2	30	20	66.7	47.2	82.7
	Grade 3	6	0	0.0	0.0	45.9	30	2	6.7	0.8	22.1
	Related	6	1	16.7	0.4	64.1	30	19	63.3	43.9	80.1
Joint pain at other location	Any	6	0	0.0	0.0	45.9	30	9	30.0	14.7	49.4
	Grade 3	6	0	0.0	0.0	45.9	30	0	0.0	0.0	11.6
	Related	6	0	0.0	0.0	45.9	30	8	26.7	12.3	45.9
Muscle aches	Any	6	0	0.0	0.0	45.9	30	11	36.7	19.9	56.1
	Grade 3	6	0	0.0	0.0	45.9	30	0	0.0	0.0	11.6
	Related	6	0	0.0	0.0	45.9	30	10	33.3	17.3	52.8
Shivering	Any	6	1	16.7	0.4	64.1	30	11	36.7	19.9	56.1
	Grade 3	6	0	0.0	0.0	45.9	30	0	0.0	0.0	11.6
	Related	6	1	16.7	0.4	64.1	30	11	36.7	19.9	56.1
Sweating	Any	6	0	0.0	0.0	45.9	30	5	16.7	5.6	34.7
	Grade 3	6	0	0.0	0.0	45.9	30	1	3.3	0.1	17.2
	Related	6	0	0.0	0.0	45.9	30	4	13.3	3.8	30.7
Temperature (Axillary)	≥ 37.5°C	6	2	33.3	4.3	77.7	30	8	26.7	12.3	45.9
	≥ 39.0°C - ≤ 40.0°C	6	0	0.0	0.0	45.9	30	3	10.0	2.1	26.5
	Related	6	1	16.7	0.4	64.1	30	8	26.7	12.3	45.9
<p>N= number of subjects with at least one documented dose  n/%= number/percentage of subjects reporting at least once the symptom  95%CI= Exact 95% confidence interval; LL = lower limit, UL = upper limit  Any= occurrence of any general symptoms regardless of their intensity grade or their relation to vaccination  Grade 3= symptom that prevented normal activity  Related= symptom assessed by the investigator as causally related to the study vaccination</p>											
<b>Secondary Outcome Variable(s):</b> Percentage of subjects reporting the occurrence of unsolicited adverse events with medically attended visit, up to 42 days after the first vaccination or 21 days after the second dose on all subjects (Total Vaccinated cohort)											
		<b>Flu [6 months-9 years] Group</b>					<b>Flu [10-17 years] Group</b>				
		<b>6m-5y</b>			<b>6y-9y</b>		<b>10-17y</b>				
		<b>N = 24</b>			<b>N = 6</b>		<b>N = 30</b>				
Subjects with any MAE(s), n (%)		9 (37.5)			2 (33.3)		6 (20.0)				
Conjunctivitis		1 (4.2)			-		-				

Ocular hyperaemia		1 (4.2)	-	-																
Diarrhoea		-	1 (16.7)	-																
Vomiting		-	1 (16.7)	-																
Pyrexia		1 (4.2)	1 (16.7)	-																
Bronchitis		1 (4.2)	-	1 (3.3)																
Exanthema subitum		1 (4.2)	-	-																
Gastroenteritis		1 (4.2)	-	-																
Influenza		1 (4.2)	-	2 (6.7)																
Nasopharyngitis		3 (12.5)	-	-																
Otitis media acute		1 (4.2)	-	-																
Pharyngitis		0 (0.0)	-	1 (3.3)																
Rhinitis		1 (4.2)	-	-																
Cough		2 (8.3)	1 (16.7)	1 (3.3)																
Rhinitis allergic		0 (0.0)	-	1 (3.3)																
Rhinorrhoea		2 (8.3)	-	-																
Upper respiratory tract inflammation		1 (4.2)	-	-																
Acne		-	-	1 (3.3)																
<b>Secondary Outcome Variable(s):</b> Percentage of subjects reporting the occurrence of potential Immune-Mediated Diseases (pIMDs), up to 42 days after the first vaccination or 21 days after the second dose on all subjects (Total Vaccinated cohort)																				
		<b>Flu [6 months-9 years] Group</b>			<b>Flu [10-17 years] Group</b>															
		<b>6m-5y N = 24</b>			<b>6y-9y N = 6</b>			<b>10-17y N = 30</b>												
Subjects with any pIMD(s), n (%)		0 (0.0)			0 (0.0)			0 (0.0)												
<b>Secondary Outcome Variable(s):</b> Distribution of biochemical parameters with respect to normal laboratory ranges on all subjects (Total Vaccinated cohort)																				
					<b>Flu [6 months-9 years] Group</b>															
					<b>6m-5y N = 24</b>						<b>6y-9y N = 6</b>									
					<b>Unknown</b>		<b>Below</b>		<b>Within</b>		<b>Above</b>		<b>Unknown</b>		<b>Below</b>		<b>Within</b>		<b>Above</b>	
<b>Laboratory parameter</b>	<b>Timing</b>	<b>N</b>	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>	<b>N</b>	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>	
ALAT	PRE	22	0	0.0	0	0.0	22	100	0	0.0	6	0	0.0	0	0.0	6	100	0	0.0	
	PI(D7)	23	0	0.0	0	0.0	23	100	0	0.0	6	0	0.0	0	0.0	6	100	0	0.0	
	PII(D42)	22	0	0.0	0	0.0	22	100	0	0.0	6	0	0.0	0	0.0	6	100	0	0.0	
Albumin	PRE	22	0	0.0	0	0.0	21	95.5	1	4.5	6	0	0.0	0	0.0	6	100	0	0.0	
	PI(D7)	23	0	0.0	0	0.0	22	95.7	1	4.3	6	0	0.0	0	0.0	6	100	0	0.0	
	PII(D42)	22	0	0.0	2	9.1	19	86.4	1	4.5	6	0	0.0	0	0.0	6	100	0	0.0	
AP	PRE	22	0	0.0	0	0.0	0	0.0	22	100	6	0	0.0	0	0.0	0	0.0	6	100	
	PI(D7)	23	0	0.0	0	0.0	0	0.0	23	100	6	0	0.0	0	0.0	0	0.0	6	100	
	PII(D42)	22	1	4.5	0	0.0	0	0.0	21	95.5	6	0	0.0	0	0.0	0	0.0	6	100	
ASAT	PRE	22	0	0.0	0	0.0	21	95.5	1	4.5	6	0	0.0	0	0.0	6	100	0	0.0	
	PI(D7)	23	0	0.0	0	0.0	21	91.3	2	8.7	6	0	0.0	0	0.0	6	100	0	0.0	
	PII(D42)	22	1	4.5	0	0.0	20	90.9	1	4.5	6	0	0.0	0	0.0	6	100	0	0.0	
Bilirubin	PRE	22	0	0.0	0	0.0	22	100	0	0.0	6	0	0.0	0	0.0	6	100	0	0.0	
	PI(D7)	23	0	0.0	0	0.0	23	100	0	0.0	6	0	0.0	0	0.0	6	100	0	0.0	
	PII(D42)	22	0	0.0	0	0.0	22	100	0	0.0	6	0	0.0	0	0.0	6	100	0	0.0	
Bilirubin Conjugated / Direct	PRE	22	0	0.0	0	0.0	22	100	0	0.0	6	0	0.0	0	0.0	6	100	0	0.0	
	PI(D7)	23	0	0.0	0	0.0	23	100	0	0.0	6	0	0.0	0	0.0	6	100	0	0.0	
	PII(D42)	22	0	0.0	0	0.0	22	100	0	0.0	6	0	0.0	0	0.0	6	100	0	0.0	
Cholesterol	PRE	22	0	0.0	7	31.8	13	59.1	2	9.1	6	0	0.0	2	33.3	4	66.7	0	0.0	
	PI(D7)	23	0	0.0	8	34.8	14	60.9	1	4.3	6	0	0.0	2	33.3	4	66.7	0	0.0	
	PII(D42)	22	0	0.0	8	36.4	14	63.6	0	0.0	6	0	0.0	2	33.3	4	66.7	0	0.0	
Chloride	PRE	22	0	0.0	0	0.0	22	100	0	0.0	6	0	0.0	0	0.0	6	100	0	0.0	
	PI(D7)	23	0	0.0	0	0.0	23	100	0	0.0	6	0	0.0	0	0.0	6	100	0	0.0	



Chloride	PRE	29	0	0.0	0	0.0	29	100	0	0.0
	PI(D7)	30	0	0.0	0	0.0	29	96.7	1	3.3
	PII(D42)	30	0	0.0	0	0.0	29	96.7	1	3.3
Creatinine	PRE	29	0	0.0	11	37.9	18	62.1	0	0.0
	PI(D7)	30	0	0.0	8	26.7	22	73.3	0	0.0
	PII(D42)	30	0	0.0	12	40.0	18	60.0	0	0.0
CK	PRE	29	0	0.0	0	0.0	28	96.6	1	3.4
	PI(D7)	30	0	0.0	0	0.0	28	93.3	2	6.7
	PII(D42)	30	0	0.0	0	0.0	27	90.0	3	10.0
GGT	PRE	29	0	0.0	0	0.0	29	100	0	0.0
	PI(D7)	30	0	0.0	0	0.0	29	96.7	1	3.3
	PII(D42)	30	0	0.0	0	0.0	29	96.7	1	3.3
Potassium	PRE	29	0	0.0	0	0.0	29	100	0	0.0
	PI(D7)	30	0	0.0	0	0.0	30	100	0	0.0
	PII(D42)	30	0	0.0	0	0.0	30	100	0	0.0
LDH	PRE	29	0	0.0	0	0.0	26	89.7	3	10.3
	PI(D7)	30	0	0.0	0	0.0	29	96.7	1	3.3
	PII(D42)	30	0	0.0	0	0.0	27	90.0	3	10.0
Sodium	PRE	29	0	0.0	0	0.0	29	100	0	0.0
	PI(D7)	30	0	0.0	0	0.0	30	100	0	0.0
	PII(D42)	30	0	0.0	0	0.0	30	100	0	0.0
Protein	PRE	29	0	0.0	4	13.8	25	86.2	0	0.0
	PI(D7)	30	0	0.0	1	3.3	29	96.7	0	0.0
	PII(D42)	30	0	0.0	3	10.0	27	90.0	0	0.0
Urate / Uric acid	PRE	29	0	0.0	0	0.0	27	93.1	2	6.9
	PI(D7)	30	0	0.0	2	6.7	26	86.7	2	6.7
	PII(D42)	30	0	0.0	2	6.7	26	86.7	2	6.7
BUN	PRE	29	0	0.0	0	0.0	29	100	0	0.0
	PI(D7)	30	0	0.0	0	0.0	30	100	0	0.0
	PII(D42)	30	0	0.0	1	3.3	28	93.3	1	3.3

N = number of subjects with laboratory results for the specified time point and laboratory parameter

n/% = number/percentage of subjects in a given category

Unknown = value unknown for the specified time point and laboratory parameter

Below = value below the laboratory reference range defined for the specified time point and laboratory parameter

Within = value within the laboratory reference range defined for the specified time point and laboratory parameter

Above = value above the laboratory reference range defined for the specified time point and laboratory parameter

ALAT= Alanine Amino Transferase

AP= Alkaline Phosphatase

ASAT= Aspartate Amino Transferase

CK= Creatine Phosphokinase

GGT= Gamma-Glutamyl Transpeptidase

LDH= Lactate dehydrogenase

BUN= Blood Urea Nitrogen

**Secondary Outcome Variable(s):** Distribution of haematology with respect to normal laboratory ranges on all subjects  
(Total Vaccinated cohort)

		Flu [6 months-9 years] Group																	
		6m-5y N = 24										6y-9y N = 6							
		Unknown		Below		Within		Above		Unknown		Below		Within		Above			
Laboratory parameter	Timing	N	n	%	n	%	n	%	n	%	N	n	%	n	%	n	%		
Baso/100WB BC	PRE	22	0	0.0	0	0.0	22	100	0	0.0	6	0	0.0	0	0.0	6	100	0	0.0
	PI(D7)	23	0	0.0	0	0.0	23	100	0	0.0	6	0	0.0	0	0.0	6	100	0	0.0
	PII(D42)	22	0	0.0	0	0.0	22	100	0	0.0	6	0	0.0	0	0.0	6	100	0	0.0
Eos/100WB C	PRE	22	0	0.0	0	0.0	18	81.8	4	18.2	6	0	0.0	0	0.0	6	100	0	0.0
	PI(D7)	23	0	0.0	0	0.0	21	91.3	2	8.7	6	0	0.0	0	0.0	6	100	0	0.0

Hematocrit	PII(D42)	22	0	0.0	0	0.0	21	95.5	1	4.5	6	0	0.0	0	0.0	6	100	0	0.0
	PRE	22	0	0.0	7	31.8	15	68.2	0	0.0	6	0	0.0	3	50.0	3	50.0	0	0.0
	PI(D7)	23	0	0.0	7	30.4	16	69.6	0	0.0	6	0	0.0	3	50.0	3	50.0	0	0.0
Hemoglobin	PII(D42)	22	0	0.0	9	40.9	13	59.1	0	0.0	6	0	0.0	3	50.0	3	50.0	0	0.0
	PRE	22	0	0.0	10	45.5	12	54.5	0	0.0	6	0	0.0	3	50.0	3	50.0	0	0.0
	PI(D7)	23	0	0.0	10	43.5	13	56.5	0	0.0	6	0	0.0	4	66.7	2	33.3	0	0.0
Lymph/100WBC	PII(D42)	22	0	0.0	12	54.5	10	45.5	0	0.0	6	0	0.0	3	50.0	3	50.0	0	0.0
	PRE	22	0	0.0	0	0.0	18	81.8	4	18.2	6	0	0.0	0	0.0	6	100	0	0.0
	PI(D7)	23	0	0.0	0	0.0	17	73.9	6	26.1	6	0	0.0	0	0.0	6	100	0	0.0
Mono/100WBC	PII(D42)	22	0	0.0	0	0.0	22	100	0	0.0	6	0	0.0	0	0.0	6	100	0	0.0
	PRE	22	0	0.0	0	0.0	21	95.5	1	4.5	6	0	0.0	0	0.0	6	100	0	0.0
	PI(D7)	23	0	0.0	0	0.0	21	91.3	2	8.7	6	0	0.0	0	0.0	6	100	0	0.0
Neut/100WBC	PII(D42)	22	0	0.0	0	0.0	22	100	0	0.0	6	0	0.0	0	0.0	6	100	0	0.0
	PRE	22	0	0.0	8	36.4	14	63.6	0	0.0	6	0	0.0	0	0.0	6	100	0	0.0
	PI(D7)	23	0	0.0	12	52.2	11	47.8	0	0.0	6	0	0.0	1	16.7	5	83.3	0	0.0
Platelets	PII(D42)	22	0	0.0	7	31.8	15	68.2	0	0.0	6	0	0.0	0	0.0	6	100	0	0.0
	PRE	22	0	0.0	1	4.5	16	72.7	5	22.7	6	0	0.0	0	0.0	6	100	0	0.0
	PI(D7)	23	0	0.0	0	0.0	14	60.9	9	39.1	6	0	0.0	0	0.0	5	83.3	1	16.7
Red Blood Cells	PII(D42)	22	0	0.0	1	4.5	13	59.1	8	36.4	6	0	0.0	0	0.0	5	83.3	1	16.7
	PRE	22	0	0.0	0	0.0	21	95.5	1	4.5	6	0	0.0	0	0.0	6	100	0	0.0
	PI(D7)	23	0	0.0	0	0.0	22	95.7	1	4.3	6	0	0.0	0	0.0	6	100	0	0.0
White Blood Cells	PII(D42)	22	0	0.0	0	0.0	20	90.9	2	9.1	6	0	0.0	1	16.7	5	83.3	0	0.0
	PRE	22	0	0.0	0	0.0	14	63.6	8	36.4	6	0	0.0	0	0.0	6	100	0	0.0
	PI(D7)	23	0	0.0	0	0.0	10	43.5	13	56.5	6	0	0.0	0	0.0	5	83.3	1	16.7
PII(D42)	22	0	0.0	0	0.0	12	54.5	10	45.5	6	0	0.0	0	0.0	4	66.7	2	33.3	

**Flu [10-17 years] Group**

		10-17y N = 30								
		Unknown		Below		Within		Above		
Laboratory parameter	Timing	N	n	%	n	%	n	%	n	%
Baso/100WBC	PRE	29	1	3.4	0	0.0	28	96.6	0	0.0
	PI(D7)	30	0	0.0	0	0.0	30	100	0	0.0
	PII(D42)	30	0	0.0	0	0.0	30	100	0	0.0
Eos/100WBC	PRE	29	1	3.4	0	0.0	23	79.3	5	17.2
	PI(D7)	30	0	0.0	0	0.0	25	83.3	5	16.7
	PII(D42)	30	0	0.0	0	0.0	27	90.0	3	10.0
Hematocrit	PRE	29	1	3.4	1	3.4	25	86.2	2	6.9
	PI(D7)	30	0	0.0	3	10.0	26	86.7	1	3.3
	PII(D42)	30	0	0.0	4	13.3	26	86.7	0	0.0
Hemoglobin	PRE	29	1	3.4	8	27.6	20	69.0	0	0.0
	PI(D7)	30	0	0.0	8	26.7	22	73.3	0	0.0
	PII(D42)	30	0	0.0	6	20.0	24	80.0	0	0.0
Lymph/100WBC	PRE	29	1	3.4	0	0.0	28	96.6	0	0.0
	PI(D7)	30	0	0.0	0	0.0	29	96.7	1	3.3
	PII(D42)	30	0	0.0	0	0.0	30	100	0	0.0
Mono/100WBC	PRE	29	1	3.4	0	0.0	27	93.1	1	3.4
	PI(D7)	30	0	0.0	0	0.0	29	96.7	1	3.3
	PII(D42)	30	0	0.0	0	0.0	28	93.3	2	6.7
Neut/100WBC	PRE	29	1	3.4	1	3.4	27	93.1	0	0.0
	PI(D7)	30	0	0.0	1	3.3	29	96.7	0	0.0
	PII(D42)	30	0	0.0	1	3.3	29	96.7	0	0.0
Platelets	PRE	29	1	3.4	0	0.0	27	93.1	1	3.4
	PI(D7)	30	0	0.0	0	0.0	29	96.7	1	3.3
	PII(D42)	30	0	0.0	0	0.0	29	96.7	1	3.3

Red Blood Cells	PRE	29	1	3.4	0	0.0	26	89.7	2	6.9
	PI(D7)	30	0	0.0	0	0.0	28	93.3	2	6.7
	PII(D42)	30	0	0.0	0	0.0	29	96.7	1	3.3
White Blood Cells	PRE	29	1	3.4	0	0.0	28	96.6	0	0.0
	PI(D7)	30	0	0.0	0	0.0	30	100	0	0.0
	PII(D42)	30	0	0.0	0	0.0	29	96.7	1	3.3

N = number of subjects with laboratory results for the specified time point and laboratory parameter

n/% = number/percentage of subjects in a given category

Unknown = value unknown for the specified time point and laboratory parameter

Below = value below the laboratory reference range defined for the specified time point and laboratory parameter

Within = value within the laboratory reference range defined for the specified time point and laboratory parameter

Above = value above the laboratory reference range defined for the specified time point and laboratory parameter

Baso= Basophils

Eos= Eosinophils

Lymph= Lymphocytes

Mono= Monocytes

Neut= Neutrophils

WBC= White Blood Cells

**Safety results:** Number (%) of subjects with unsolicited adverse events up to 42 days after the first vaccination or 21 days after the second dose (Total Vaccinated cohort)

<b>Most frequent adverse events - On-Therapy (occurring within day 0-41 following vaccination)</b>	<b>Flu [6 months-9 years] Group N = 30</b>	<b>Flu [10-17 years] Group N = 30</b>
Subjects with any AE(s), n (%)	17 (56.7)	15 (50.0)
Subjects with grade 3 AE(s), n (%)	4 (13.3)	4 (13.3)
Subjects with related AE(s), n (%)	9 (30.0)	8 (26.7)
Cough	7 (23.3)	2 (6.7)
Rhinorrhoea	7 (23.3)	1 (3.3)
Pyrexia	5 (16.7)	-
Diarrhoea	3 (10.0)	-
Nasopharyngitis	3 (10.0)	-
Axillary pain	-	2 (6.7)
Eye discharge	2 (6.7)	-
Influenza	1 (3.3)	2 (6.7)
Rhinitis allergic	-	2 (6.7)
Vomiting	2 (6.7)	-
Conjunctivitis	1 (3.3)	-
Ocular hyperaemia	1 (3.3)	-
Irritability	1 (3.3)	-
Bronchitis	1 (3.3)	1 (3.3)
Exanthema subitum	1 (3.3)	-
Gastroenteritis	1 (3.3)	-
Otitis media acute	1 (3.3)	-
Rhinitis	1 (3.3)	-
Decreased appetite	1 (3.3)	-
Crying	1 (3.3)	-
Insomnia	1 (3.3)	-
Sneezing	1 (3.3)	-
Upper respiratory tract inflammation	1 (3.3)	-
Dermatitis diaper	1 (3.3)	-
Dry skin	1 (3.3)	-
Pruritus	1 (3.3)	-
Rash	1 (3.3)	-
Lymphadenopathy	-	1 (3.3)
Injection site haemorrhage	-	1 (3.3)
Pharyngitis	-	1 (3.3)

Headache	-	1 (3.3)
Dysmenorrhoea	-	1 (3.3)
Dyspnoea	-	1 (3.3)
Epistaxis	-	1 (3.3)
Oropharyngeal pain	-	1 (3.3)
Acne	-	1 (3.3)
Eczema	-	1 (3.3)
Urticaria	-	1 (3.3)
- : Adverse event absent Grade 3= event that prevented normal activity Related= event assessed by the investigator as causally related to the study vaccination		
<b>Safety results:</b> Number (%) of subjects with serious adverse events up to 42 days after the first vaccination or 21 days after the second dose (Total Vaccinated cohort)		
<b>Serious adverse event, n (%) [n considered by the investigator to be related to study medication]</b>		
<b>All SAEs</b>	<b>Flu [6 months-9 years] Group N = 30</b>	<b>Flu [10-17 years] Group N = 30</b>
Subjects with any SAE(s), n (%) [n assessed by investigator as related]	0 (0.0) [0]	0 (0.0) [0]
<b>Fatal SAEs</b>	<b>Flu [6 months-9 years] Group N = 30</b>	<b>Flu [10-17 years] Group N = 30</b>
Subjects with fatal SAE(s), n (%) [n assessed by investigator as related]	0 (0.0) [0]	0 (0.0) [0]

**Conclusion:**

At Day 42, 21 days after the second dose of Flu vaccine, the GMT value for HI antibodies against A/California/7/2009 (H1N1)v-like was 939.3 in Flu [6 months-9 years] Group and 874.3 in Flu [10-17 years] Group and the SCR was 100% for all subjects. At this time point, all subjects had reached the HI antibody titre that usually is accepted as indicating protection and the SCF value was 146.8 in Flu [6 months-9 years] Group and 57.1 in Flu [10-17 years] Group. During the 42-day follow-up period following the first dose, at least one unsolicited AE was reported for 17 (56.7%) subjects aged 6 months to 9 years and 15 (50.0%) subjects aged 10 to 17 years. No SAE was reported up to Day 42.

**Publications:** None

Date updated: 21-Apr-2010